Jun 2026 (Q2 FY26) — Aug 6, 2026
Praxis Precision Medicines Q2 FY26 — Dual NDA Progress and Commercial Readiness
Read the full callPraxis Precision Medicines (PRAX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Praxis Precision Medicines earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -83.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$248.24 +3.86% · +$9.22
Performance +372.7% 1Y
1Y: $52.52 on 14 Oct 2025 → $248.24. High $386.33 (12 Aug 2026), low $52.52 (14 Oct 2025).
- Previous close
- $239.02
- 52-week range
- $52.52 – $386.33
- One year
- +332.85%
Overview
- Symbol
- PRAX
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 7, 2026
Praxis Precision Medicines Q1 FY26 — Late-Stage Assets Progress, Commercial Ramp, and Pipeline Catalysts
Read the full callEvery analysed call
Praxis Precision Medicines earnings calls (PRAX)
Financials
What the filings say
Net profit, year on year: −18% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 7 | 0 | 0 | 0 | 0 | — | — |
| Operating profit | -57 | -64 | -75 | -76 | -78 | -97 | -106 | -97 |
| Operating margin | −18819.5% | −857.0% | — | — | — | — | — | — |
| Other income | 5 | 5 | 5 | 5 | 4 | 8 | 13 | 13 |
| Net profit | -52 | -59 | -69 | -71 | -74 | -89 | -93 | -84 |
| EPS ($ per share) | -2.75 | — | -3.29 | -3.31 | -3.36 | — | -3.20 | -2.87 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -81 | -150 | -317 | -531 | -654 | -837 | -1,140 |
| Total liabilities | 8 | 16 | 42 | 39 | 18 | 38 | 60 |
| Fixed assets | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| Investments | — | — | — | — | — | 177 | 242 |
| Total assets | 48 | 303 | 293 | 115 | 88 | 483 | 938 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -33 | -53 | -125 | -185 | -111 | -132 | -249 |
| Cash from investing | -0 | 0 | -141 | 97 | 39 | -248 | -311 |
| Cash from financing | 60 | 304 | 108 | 10 | 92 | 514 | 702 |
| Net cash flow | 27 | 252 | -157 | -78 | 20 | 134 | 142 |
| Capital expenditure | -0 | 0 | -1 | -0 | -0 | 0 | -0 |
| Free cash flow | -34 | -53 | -126 | -185 | -111 | -132 | -249 |
PRAX revenue by segment
| Segment | Q1 FY2024 | Q2 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|
| Reportable | — | — | — | — | — | — | — |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Insider filings
81 filings between Oct 16, 2025 and Jul 8, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$44.27M
28 sales by 4 insiders
43% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 23
- Award — granted as compensation
- 14
- Option exercise — converted options into shares
- 13
- Tax withheld — shares kept back by the company to cover tax
Also filed: 3 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Adage Capital Management, L.P. | — | $33.20M | Oct 16, 2025 |
| Nemiroff Alex | — | $4.85M | Nov 20, 2025 |
| DeSimone Jill | — | $3.61M | Jun 24, 2026 |
| Mastrocola Lauren | — | $2.61M | Nov 20, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 8, 2026 | Souza Marcio Chief Executive Officer | Gift | 2,600 | $0 |
| Jul 8, 2026 | Souza Marcio Chief Executive Officer | Gift | 20,521 | $0 |
| Jun 24, 2026 | DeSimone Jill Director | Sale 10b5-1 plan | 10 | $3.0K |
| Jun 24, 2026 | DeSimone Jill Director | Sale 10b5-1 plan | 120 | $36.4K |
| Jun 24, 2026 | DeSimone Jill Director | Option exercise 10b5-1 plan | 8,566 | $379.0K |
| Jun 24, 2026 | DeSimone Jill Director | Sale 10b5-1 plan | 1,279 | $402.8K |
| Jun 24, 2026 | DeSimone Jill Director | Sale 10b5-1 plan | 837 | $264.2K |
| Jun 24, 2026 | DeSimone Jill Director | Sale 10b5-1 plan | 1,240 | $382.2K |
| Jun 24, 2026 | DeSimone Jill Director | Option exercise 10b5-1 plan | 3,034 | $446.9K |
| Jun 24, 2026 | DeSimone Jill Director | Sale 10b5-1 plan | 2,854 | $890.2K |
| Jun 24, 2026 | DeSimone Jill Director | Sale 10b5-1 plan | 1,750 | $544.1K |
| Jun 24, 2026 | DeSimone Jill Director | Sale 10b5-1 plan | 1,004 | $314.1K |
| Jun 24, 2026 | DeSimone Jill Director | Sale 10b5-1 plan | 320 | $97.7K |
| Jun 24, 2026 | DeSimone Jill Director | Sale 10b5-1 plan | 504 | $158.1K |
| Jun 24, 2026 | DeSimone Jill Director | Sale 10b5-1 plan | 999 | $309.1K |
| Jun 24, 2026 | DeSimone Jill Director | Sale 10b5-1 plan | 683 | $209.5K |
| Jun 10, 2026 | Arbuckle Stuart A Director | Award | 1,371 | $0 |
| Jun 10, 2026 | Norden Gregory Director | Award | 1,371 | $0 |
| Jun 10, 2026 | YOUNG WILLIAM D Director | Award | 1,371 | $0 |
| Jun 10, 2026 | Chodakewitz Jeffrey Director | Award | 1,371 | $0 |
| Jun 10, 2026 | DeSimone Jill Director | Award | 1,371 | $0 |
| Jun 10, 2026 | Cudkowicz Merit Ester Director | Award | 1,371 | $0 |
| Jun 10, 2026 | KINDLER JEFFREY B Director | Award | 1,371 | $0 |
| Jun 10, 2026 | MITCHELL DEAN J Director | Award | 1,371 | $0 |
| May 14, 2026 | Souza Marcio Chief Executive Officer | Award | 126 | $21.2K |
| May 14, 2026 | Nemiroff Alex General Counsel and Secretary | Award | 78 | $13.1K |
| May 14, 2026 | Kelly Timothy Edwin Chief Financial Officer | Award | 121 | $20.3K |
| May 14, 2026 | Sniecinski Megan Chief Operating Officer | Award | 89 | $14.9K |
| May 14, 2026 | Mastrocola Lauren Principal Accounting Officer | Award | 127 | $21.3K |
| Feb 6, 2026 | KINDLER JEFFREY B Director | Award | 478 | $0 |
| Feb 6, 2026 | KINDLER JEFFREY B Director | Award | 688 | $0 |
| Feb 6, 2026 | Arbuckle Stuart A Director | Award | 478 | $0 |
| Feb 6, 2026 | Arbuckle Stuart A Director | Award | 688 | $0 |
| Jan 12, 2026 | Nemiroff Alex General Counsel and Secretary | Tax withheld | 768 | $211.8K |
| Jan 12, 2026 | Mastrocola Lauren Principal Accounting Officer | Tax withheld | 344 | $94.9K |
| Jan 12, 2026 | Sniecinski Megan Chief Operating Officer | Tax withheld | 885 | $244.0K |
| Jan 12, 2026 | Kelly Timothy Edwin Chief Financial Officer | Tax withheld | 943 | $260.0K |
| Jan 10, 2026 | Mastrocola Lauren Principal Accounting Officer | Tax withheld | 367 | $105.9K |
| Jan 10, 2026 | Sniecinski Megan Chief Operating Officer | Tax withheld | 1,087 | $313.5K |
| Jan 10, 2026 | Nemiroff Alex General Counsel and Secretary | Tax withheld | 917 | $264.5K |
| Jan 10, 2026 | Souza Marcio Chief Executive Officer | Tax withheld | 4,252 | $1.23M |
| Jan 10, 2026 | Kelly Timothy Edwin Chief Financial Officer | Tax withheld | 1,335 | $385.1K |
| Jan 8, 2026 | Nemiroff Alex General Counsel and Secretary | Award | 6,875 | $0 |
| Jan 8, 2026 | Mastrocola Lauren Principal Accounting Officer | Award | 3,750 | $0 |
| Jan 8, 2026 | Sniecinski Megan Chief Operating Officer | Award | 9,625 | $0 |
| Jan 8, 2026 | Kelly Timothy Edwin Chief Financial Officer | Award | 8,800 | $0 |
| Jan 8, 2026 | Souza Marcio Chief Executive Officer | Award | 27,640 | $0 |
| Jan 7, 2026 | Nemiroff Alex General Counsel and Secretary | Tax withheld | 89 | $26.0K |
| Jan 7, 2026 | Mastrocola Lauren Principal Accounting Officer | Tax withheld | 35 | $10.2K |
| Jan 7, 2026 | Souza Marcio Chief Executive Officer | Tax withheld | 405 | $118.5K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Praxis Precision Medicines, Inc.
Free account. Everything above stays public.
Write why you follow Praxis Precision Medicines, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading